Lunchtime Leaders 13 Feb 2024

DENVER, Colo., Feb. 13, 2024 ( Today’s big trades include (NASDAQ:OMH), (AMEX:AULT), (NASDAQ:BMR), (NASDAQ:BGLC), (NASDAQ:BTAI), (NASDAQ:LIAN)

Ohmyhome (NASDAQ:OMH) is well below today’s $6.00 high, trading at $2.81 (+130.74%), on 73.9M shares.

“Ohmyhome is a one-stop-shop property technology platform in Singapore that provides end-to-end property solutions and services to buy, sell, rent, and renovate homes, as well as property management services for condominiums in Singapore. Since its launch in 2016, Ohmyhome has transacted over 14,500 properties, and has over 5,800 units under management as of June 30, 2023. It is also the highest-rated property transaction platform, with more than 8,000 genuine reviews, and an average rating of 4.9 out of 5 stars.”

Ault Alliance (AMEX:AULT) is below today’s $1.05 high and is trading at $0.5744 (+39.11%), on 59M shares.

“Under the Repurchase Program, the Board authorized the Company to repurchase up to $50 million of common stock, which repurchases may be made on a discretionary basis from time to time through a variety of methods, including open market repurchases. The Company intends to enact a trading plan (the “Rule 10b5-1 Plan”) for the repurchases in compliance with the Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the rules of the United States Securities and Exchange Commission and other applicable federal and state rules and regulations. The Rule 10b5-1 Plan will allow the Company to execute trades during periods when it would otherwise not be permitted to do so because it may be in possession of material non-public information, because of insider trading laws or self-imposed trading blackout periods. Under the Rule 10b5-1 Plan, the executing broker would have the authority, under the prices, terms and limitations set forth in the Rule 10b5-1 Plan, including compliance with Rule 10b-18 of the Exchange Act (“Rule 10b-18”), to repurchase shares on the Company’s behalf. In accordance with Rule 10b-18, the Repurchase Program is not intended to constitute a going-private transaction.”

Beamr Imaging (NASDAQ:BMR) was our big trade, yesterday, following joint research presentation, with NVIDIA Corporation, news, relating to automated video modernization.

We covered BMR when it was trading at $3.57 and it’s now trading at $14.62 (+46.88%), hit a high of $21.70 and 36.7M shares.

“Beamr Imaging Ltd. (“Beamr” or the “Company”), a leader in video optimization technology, today announced the pricing of an underwritten public offering of 1,714,200 ordinary shares. Each ordinary share is being sold at a public offering price of $7.00 per share for gross proceeds of approximately $12 million, before deducting underwriting discounts and offering expenses. All of the ordinary shares are being offered by the Company. In addition, Beamr has granted the underwriters a 45-day option to purchase up to an additional 257,100 ordinary shares to cover over-allotments at the public offering price, less the underwriting discount.”

BioNexus Gene Lab (NASDAQ:BGLC) is trading at $1.73 (+321.75%), on 39.8M shares and its high of the day is $2.45.

“BioNexus Gene Lb Corp. is developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of disease risks derived from evidence-based research to minimize treatment costs and improve patient management on his current health status. Our non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.”

BioXcel Therapeutics (NASDAQ:BTAI) is trading at $2.40 (+23.03%), on 9.6M shares and its high of the day is $2.57.

“BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has terminated its proposed public offering of $60.0 million of shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, previously announced on February 8, 2024. As a result of such termination, no securities of the Company are being sold pursuant to the offering.”

LianBio (NASDAQ:LIAN) is trading at $4.77 (+18.07%), on 5.5M shares and its high of the day is $4.88.

“LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the Company’s Board of Directors (the “Board”) had completed its comprehensive strategic review of the Company and determined to initiate the wind down of its operations, including the sale of remaining pipeline assets, the delisting of its American Depositary Shares (“ADSs”), each representing the right to receive one ordinary share, from the Nasdaq Global Market (“Nasdaq”) and deregistration under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and workforce reductions. The Company currently anticipates a substantial portion of the wind down activities, including fulfillment of transition service obligations under its existing agreements and gradual cessation of currently active clinical trials, will be completed by the end of 2024. In parallel with the wind down of operations, the Board has declared a special cash dividend in the amount of $4.80 per ordinary share, including ordinary shares represented by ADSs, for an aggregate cash dividend amount of approximately $528 million.”

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Few succeed in the stock market. Don’t trade if you’re not able to devote the necessary time. Earmark your surplus funds that you’re prepared to lose. Assess your risk appetite and set your stops accordingly, and honor your stop losses. Always employ loss limiting strategies. Be prepared to be blindsided by hidden risks, a bad company financing or other move can turn gains into losses.

Learn technical analysis, charting, patterns, and setups. Buying at the bottom and selling at the top is a myth. The middle half of a move is the sweet spot and learn how to exit a winning position, because trying to time the exact top can turn into big losses. Trade small and take advantage of small price move strategies, like scalping.

Remove emotional and psychological biases, and consider that you’re competing against professionals who’re deploying a number of powerful stock market tools. Successful traders make more on their winners than they lose on their losers. Learn how to interpret the ECN/Level 2 data.

Please go to or for further information.

24/7 Market News
[email protected]

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.